MX2019000887A - Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc. - Google Patents
Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc.Info
- Publication number
- MX2019000887A MX2019000887A MX2019000887A MX2019000887A MX2019000887A MX 2019000887 A MX2019000887 A MX 2019000887A MX 2019000887 A MX2019000887 A MX 2019000887A MX 2019000887 A MX2019000887 A MX 2019000887A MX 2019000887 A MX2019000887 A MX 2019000887A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- enhanced
- compositions
- receptor binding
- human protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Abstract
La presente invención involucra una serie de formas multimerizadas y completamente recombinantes de inmunoglobina Fc que por lo tanto presentan inmunoglobina Fc polivalente a receptores de células inmunitarias; las proteínas de fusión existen como fracciones tanto homodiméricas como multiméricas altamente ordenadas, llamadas estradómeros; la invención involucra proteínas de fusión que se unen a FcyRs y que complementan y que son útiles en el tratamiento y prevención de enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662365921P | 2016-07-22 | 2016-07-22 | |
US201662365919P | 2016-07-22 | 2016-07-22 | |
PCT/US2017/043538 WO2018018047A2 (en) | 2016-07-22 | 2017-07-24 | Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000887A true MX2019000887A (es) | 2019-09-04 |
Family
ID=60992683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000887A MX2019000887A (es) | 2016-07-22 | 2017-07-24 | Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20190389941A1 (es) |
EP (1) | EP3487534A4 (es) |
JP (1) | JP2019530642A (es) |
KR (1) | KR20190032392A (es) |
CN (1) | CN109641048A (es) |
AU (1) | AU2017300794A1 (es) |
BR (1) | BR112019001156A2 (es) |
CA (1) | CA3029744A1 (es) |
IL (1) | IL264257A (es) |
MX (1) | MX2019000887A (es) |
SG (1) | SG11201900427PA (es) |
WO (1) | WO2018018047A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3464347B1 (en) | 2016-06-07 | 2023-05-31 | Gliknik Inc. | Cysteine-optimized stradomers |
KR20190095929A (ko) | 2016-12-09 | 2019-08-16 | 글리크닉 인코포레이티드 | 다합체화 스트라도머인 gl-2045의 제조 최적화 |
WO2018107082A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Methods of treating inflammatory disorders with multivalent fc compounds |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2109362T3 (es) | 1991-06-21 | 1998-01-16 | Univ Cincinnati | Unas proteinas administrables oralmente y metodo para hacerlas. |
EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
EP2641913B1 (en) | 2007-06-01 | 2018-04-18 | University of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
WO2009079242A2 (en) * | 2007-12-05 | 2009-06-25 | Massachusetts Institute Of Technology | Aglycosylated immunoglobulin mutants |
WO2010065578A2 (en) | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
US20120100140A1 (en) * | 2009-01-23 | 2012-04-26 | Biogen Idec Ma Inc. | Stabilized fc polypeptides with reduced effector function and methods of use |
TWI588157B (zh) | 2010-07-28 | 2017-06-21 | 吉林尼克公司 | 產生依序多聚體化免疫球蛋白fc組合物之天然人類蛋白質片段之融合蛋白 |
JP6628966B2 (ja) * | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
AU2013285355A1 (en) * | 2012-07-06 | 2015-01-29 | Genmab B.V. | Dimeric protein with triple mutations |
EP2908914B1 (en) | 2012-10-17 | 2018-04-18 | Liverpool School of Tropical Medicine | Immunomodulatory proteins |
BR112016020377A2 (pt) | 2014-03-05 | 2018-01-23 | Ucb Biopharma Sprl | proteínas fc multiméricas |
AU2015226100B2 (en) | 2014-03-05 | 2020-05-07 | UCB Biopharma SRL | Multimeric Fc proteins |
BR112016023948A2 (pt) | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
CA2941072A1 (en) | 2014-05-02 | 2015-11-05 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
GB201412821D0 (en) | 2014-07-18 | 2014-09-03 | Liverpool School Tropical Medicine | Polymeric proteins and uses thereof |
EP3789399A1 (en) * | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP3265131A1 (en) | 2015-03-05 | 2018-01-10 | UCB Biopharma SPRL | Polymeric fc proteins and methods of screening to alter their functional characteristics |
GB201511787D0 (en) | 2015-07-06 | 2015-08-19 | Ucb Biopharma Sprl | Proteins |
GB201513033D0 (en) | 2015-07-23 | 2015-09-09 | Ucb Biopharma Sprl | Proteins |
RU2020138007A (ru) | 2015-07-24 | 2020-12-17 | Гликник Инк. | Гибридные белки фрагментов белков человека для создания упорядоченно мультимеризованных композиций областей fc иммуноглобулинов с усиленным связыванием с системой комплемента |
GB201515745D0 (en) | 2015-09-04 | 2015-10-21 | Ucb Biopharma Sprl | Proteins |
-
2017
- 2017-07-24 EP EP17832021.4A patent/EP3487534A4/en not_active Withdrawn
- 2017-07-24 AU AU2017300794A patent/AU2017300794A1/en not_active Abandoned
- 2017-07-24 CA CA3029744A patent/CA3029744A1/en not_active Abandoned
- 2017-07-24 SG SG11201900427PA patent/SG11201900427PA/en unknown
- 2017-07-24 WO PCT/US2017/043538 patent/WO2018018047A2/en unknown
- 2017-07-24 US US16/315,871 patent/US20190389941A1/en not_active Abandoned
- 2017-07-24 KR KR1020197002603A patent/KR20190032392A/ko not_active Application Discontinuation
- 2017-07-24 BR BR112019001156-0A patent/BR112019001156A2/pt not_active IP Right Cessation
- 2017-07-24 CN CN201780049862.5A patent/CN109641048A/zh active Pending
- 2017-07-24 MX MX2019000887A patent/MX2019000887A/es unknown
- 2017-07-24 JP JP2019503285A patent/JP2019530642A/ja active Pending
-
2019
- 2019-01-15 IL IL264257A patent/IL264257A/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11201900427PA (en) | 2019-02-27 |
WO2018018047A2 (en) | 2018-01-25 |
JP2019530642A (ja) | 2019-10-24 |
CN109641048A (zh) | 2019-04-16 |
WO2018018047A3 (en) | 2018-03-01 |
EP3487534A4 (en) | 2020-03-25 |
BR112019001156A2 (pt) | 2019-04-30 |
CA3029744A1 (en) | 2018-01-25 |
US20190389941A1 (en) | 2019-12-26 |
EP3487534A2 (en) | 2019-05-29 |
AU2017300794A1 (en) | 2019-01-24 |
KR20190032392A (ko) | 2019-03-27 |
IL264257A (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022008337A (es) | Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada. | |
MX2019012016A (es) | Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente. | |
PH12017500892A1 (en) | Antigen binding molecules comprising a tnf family ligand trimer | |
MX2016010951A (es) | Proteinas de fc multimericas. | |
MY194669A (en) | Binding Proteins and Methods of use Thereof | |
GEP201706794B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
MX2016010953A (es) | Proteinas de fc multimericas. | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
WO2017006052A3 (fr) | UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE | |
MX2018014456A (es) | Anticuerpos contra alfa-sinucleina y sus usos. | |
MX2017003247A (es) | Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas. | |
MX2019000887A (es) | Proteínas de fusión de fragmentos de proteínas humanas para crear composiciones de fc de inmunoglobina multimerizadas en un orden con unión mejorada al receptor de fc. | |
EA201892063A1 (ru) | МОДИФИЦИРОВАННЫЕ ИММУНОГЛОБУЛИНЫ С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ FcRn | |
MX2017007747A (es) | Anticuerpos para il-17c. | |
GB2543713A (en) | Polymeric proteins and uses thereof | |
PH12018501674A1 (en) | Anti-citrullinated hla polypeptide antibodies and uses thereof | |
PE20161397A1 (es) | Compuestos de vegfr2/ang2 | |
WO2016040767A3 (en) | Chrdl-1 epitopes and antibodies |